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Evaluation of Tumor Angiogenesis with a
Second-Generation US Contrast Medium
in a Rat Breast Tumor Model
Objective: Tumor angiogenesis is an important factor for tumor growth, treat-
ment response and prognosis. Noninvasive imaging methods for the evaluation
of tumor angiogenesis have been studied, but a method for the quantification of
tumor angiogenesis has not been established. This study was designed to evalu-
ate tumor angiogenesis in a rat breast tumor model by the use of a contrast-
enhanced ultrasound (US) examination with a second-generation US contrast
agent.
Materials and Methods: The alkylating agent 19N-ethyl-N-nitrosourea (ENU)
was injected into the intraperitoneal cavity of 30-day-old female Sprague-Dawley
rats. Three to four months later, breast tumors were detected along the mammary
lines of the rats. A total of 17 breast tumors larger than 1 cm in nine rats were
evaluated by gray-scale US, color Doppler US and contrast-enhanced US using
SonoVue. The results were recorded as digital video images; time-intensity
curves and hemodynamic parameters were analyzed. Pathological breast tumor
specimens were obtained just after the US examinations. The tumor specimens
were stained with hematoxylin and eosin (H & E) and the expression of CD31, an
endothelial cell marker, was determined by immunohistochemical staining. We
also evaluated the pathological diagnosis of the tumors and the microvessel den-
sity (MVD). Spearman’s correlation and the Kruskal-Wallis test were used for the
analysis.
Results: The pathological diagnoses were 11 invasive ductal carcinomas and
six benign intraductal epithelial proliferations. The MVD did not correlate with the
pathological diagnosis. However, blood volume (BV) showed a statistically signifi-
cant correlation with MVD (Spearman’s correlation, p < 0.05).
Conclusion: Contrast-enhanced US using a second-generation US contrast
material was useful for the evaluation of tumor angiogenesis of breast tumors in
the rat.
umor angiogenesis is crucial for cancer growth and is a significant
prognostic indicator in breast cancer. Invasive breast carcinomas with
higher microvessel counts show more lymph node metastases, more
distance metastases, and a higher rate of recurrence (1, 2). In patients receiving
chemotherapy, determination of tumor angiogenesis can be used to monitor the
response to treatment (3). Many studies have evaluated tumor angiogenesis through
noninvasive imaging methods. MRI with dynamic contrast enhancement, including T1-
weighted and T2-weighted angiogenesis MRI, is the most common method for evaluat-
ing angiogenesis (4 6). Some studies have suggested that contrast enhancement of
MRI, especially early signal enhancement or early signal enhancement with rapid
washout of intravenous contrast correlates with intratumoral microvessel density
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T(MVD) representing tumor angiogenesis (7, 8), and other
studies have suggested that the degree and pattern of
contrast enhancement is correlated with the density and
distribution of microvessels (9). However, other studies
have suggested that there was no significant correlation
between contrast enhancement of MRI and MVD (10, 11).
Color and power Doppler ultrasound (US) are also used
to evaluate tumor vascularity, but these modalities can
detect only larger vessels with signals above the noise level
or flow velocities above the threshold of the wall filter.
Unfortunately, quantification methods for tumor angiogen-
esis have not yet been established.
Contrast-enhanced US imaging using second-generation
contrast medium and a low-mechanical index (MI) can
overcome the limitation of detection of only the fast blood
flow of large vessels of the above-described methods. The
purpose of this study is to evaluate quantification of tumor
angiogenesis in a rat breast tumor model by the use of a
contrast-enhanced US examination with a second-genera-
tion US contrast medium.
MATERIALS AND METHODS
The Institutional Committee for Animal Research
approved this study, which was in accordance with the
guidelines and the recommendations of the Committee on
Animal Research at Asan Medical Center.
Rat Breast Tumor Model
Breast tumors were induced by injection of the alkylat-
ing agent 19N-ethyl-N-nitrosourea (ENU) into the
peritoneal cavities of 30-day-old specific pathogen-free
(SPF) female Sprague-Dawley rats with a 70 80 gram
body weight. ENU is a strong carcinogen, inducing various
types of tumors at various sites. We administrated 180
mg/kg and 45 mg/kg of ENU to 10 and 20 rats for the
induction of malignant and benign breast tumors, respec-
tively (12).
After three to four months, tumors developed along the
mammary lines from the axilla to inguinal areas in seven
rats in the malignant group and five rats in the benign
group. Among the lesions, we selected tumors larger than
1 cm in size for inclusion in an US examination. A total of
17 mammary tumors from nine rats were included in the
study.
US Examinations
US images were obtained with a Logic 9 unit (GE
Medical Systems, Milwaukee, WI) using a 10-MHz linear
array probe. US parameters including acoustic gain, depth,
and focus were optimized for each tumor. Conventional
and color Doppler US examinations were performed on all
lesions before the contrast-enhanced study. Gray-scale
images along the axis of the tumors, where the shape of
the entire tumor was well demonstrated, were obtained to
evaluate tumor size and shape. On color Doppler US, we
evaluated the vascularity within the tumors and the flow of
the input arteries around the tumors; these arteries were
used as reference arteries in analyzing tumor angiogenesis.
Contrast-enhanced US images were obtained using a
second-generation US contrast agent (SonoVue ; Bracco
SpA, Milan, Italy), which consists of microbubbles that
contain a hydrophobic gas (sulfur hexafluoride) instead of
air. We rapidly infused 0.25 ml/kg of the US contrast agent
followed by a 0.3 ml saline flush intravenously through the
tail vein of the rats. Contrast-enhanced US images were
obtained with a pulse-inversion coded harmonic US
technique with a low MI of 0.12. Continuous scanning
started immediately after injection of the US contrast agent
and lasted for 90 seconds. All contrast-enhanced US
studies were recorded as digital video images.
Analysis of the US Images
After recording the US examinations, we restored the
digital video images on a desktop computer. The US
images were analyzed with custom-made software (single
compartment angiogenesis analyzing program) using
Matlab 7.0 (The MathWorks. Inc., Natick, MA).
Time-intensity curves (TICs) were derived by tracking
changes in contrast signals on a pixel-by-pixel basis from
the contrast-enhanced US images after setting the region of
interest (ROI). The TICs of contrast-enhanced US images
differed from pixel to pixel within the same tumor, and the
hemodynamic parameters derived from the TICs analysis
of the ROI was influenced by the area included in the ROI.
In particular, the signal intensity (SI) of contrast increased
greatly when a vessel visible on color Doppler US was
included in the ROI. Therefore, we set the ROI in the well-
enhancing parenchyma of the tumor around 1,000 pixels,
avoiding vessels observed on the color Doppler US before
contrast-enhanced US imaging (Fig. 1). We used the mean
of calculated parameters from the TICs in three different
ROIs.
In order to extract quantitative hemodynamic parame-
ters, the SI time curves were fitted to a gamma variate
function described by the equation (13 15)
Ctissue (t) = K (t T0) e
(t T
0
)/ +S I base [1]
where t is the time, and Ctissue(t) is the measured SI as a
function of time which is related to the concentration of
the dye. K is a constant scale factor.  ,  are parameters
that define the shape of the curve. SIbase is base signal and
Ko et al.
244 Korean J Radiol 9(3), June 2008T0 is time of arrival. From the fitted values for  and  , one
can deduce perfusion indices such as the time to reach
peak concentration (tp) and the apparent mean transit time
( app) as follows (15):
tp =  [2]
app =  ( + 1) [3]
Additionally, from measurements of the tissue and
arterial concentration curves (Ctissue[t] and Carterial[t]) the
volume of distribution of the agent was calculated directly
as follows (14):
0    Ctissue (t) dt
V =
0    Carterial (t) dt
[4]
The central volume principle relates the terms perfusion
(f), blood tissue partition coefficient (p) and the mean
transit time ( ) (13, 15):
f = p /  [5]
This principle applies to any agent, whether it is
extracted from the blood or not. We assumed that contrast
agents behave as intravascular agents during the first pass.
Therefore, the mean transit time equals  app and the
partition coefficient can be determined as the distribution
volume (V). 
f = p /  = V /  app [6]
These hemodynamic parameters, including blood volume
(BV), blood flow (Q), mean transit time (MTT,  app), time
to arrival (TA), and relative time to arrival (rTA), were
obtained from the TICs of the first-pass (5, 13 16). The
TICs of the input arteries of tumors were used as the
reference of the arterial input function.
Correlation of the US findings with the Pathological
Findings
After contrast-enhanced US imaging, rats were sacrificed
by IV injection of a lethal dose of anesthetic agents.
Pathological specimens were stained with hematoxylin and
eosin (H & E) and with a specific immunohistochemical
stain for CD31 for a histological diagnosis of the tumors,
and to determine the MVD. The MVD was defined as the
total number of vessels counted within six high-power
fields ( 200) of the tumor parenchyma that had the
highest microvessel counts, except for vessels within the
muscular walls.
We evaluated the correlations between hemodynamic
parameters from contrast-enhanced US images, MVD and
the histological diagnosis using Spearman’s correlation and
the Kruskal-Wallis test.
RESULTS
In all cases, the input arteries were relatively well
visulized on color and power Doppler US examinations
before the contrast-enhanced US examinations. When
there were multiple input arteries, the largest one was
selected as a reference artery. The hemodynamic parame-
ters measured from the TICs of the contrast-enhanced US
are shown in Table 1. BV ranged from 3.10 to 12.87, and
Q ranged from 42.56 to 137.32.
When analyzing the hemodynamic parameters from the
TICs derived from the contrast-enhanced US images, BV
showed a statistically significant correlation with tumor
MVD (p < 0.05); however, the other parameters did not
correlate with MVD (Table 2).
The histological diagnoses of the tumors were 11
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Fig. 1. US results of intraductal proliferation. Color Doppler US (A) shows input artery in right side of tumor (arrow) and intratumoral
vasculature within tumor (arrowhead). Time-intensity curve of tumor (B) was obtained from three areas of enhancing parenchyma without
vascular structures within tumor.
ABinvasive ductal carcinomas (IDC) and six benign intraduc-
tal epithelial proliferations (IP) (Fig. 2). As these tumors
were induced by intraperitoneal administration of a
carcinogen, the histological features of the rat breast
tumors were not the same as those of human breast tumors
that naturally develop; even the benign intraductal prolif-
eration consisted of somewhat atypical cells and there
were no areas with normal glandular structures due to
exposure to the carcinogen. However, the histological
diagnoses were based on areas with findings relatively
typical of breast tumors. MVD counted in six high-power
fields ( 200) varied from 27 to 176 (Fig. 3). MVD did not
correlate with the histological diagnosis of the tumors. In
addition, the hemodynamic parameters driven from TICs
of contrast-enhanced US also did not correlate with the
histological diagnosis of the tumor. The histological diagno-
sis and MVD of each tumor are shown in Table 3.
DISCUSSION
Color or power Doppler US has been used to evaluate
vascularity within tumors to evaluate the characteristics of
breast lesions. However, Doppler US is not sensitive to the
slow flow and small volume blood flows in capillaries
within the tumor parenchyma. In malignant tumors with
increased interstitial pressure, slow intratumoral blood
flow is particularly difficult to evaluate with color Doppler
US (17). Power Doppler US can compensate for slow
blood flow to some degree, but flow that is visible on
Ko et al.
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Fig. 2. Invasive ductal carcinoma induced by intraperitoneal
injection of ethyl-N-nitrosourea. Tumor consists of infiltrating
cords and tubules in background of atypical ductal hyperplasia.
Arrows on right side indicate tumor necrosis (Hematoxylin &
Eosin staining, 100).
Fig. 3. Immunostaining for CD31. Endothelial cells (arrows) lining
lymphovascular spaces are immunoreactive for CD31 ( 200).
Table 1. Parameters of Tumor Angiogenesis on Contrast-
Enhanced US
Number of 
Tumor
BV Q TA/rTA MTT
01 5.88 61.18 22.27 5.31
02 4.65 66.74 22.04 3.88
03 11.64 137.32 8.39 5.31
04 12.67 72.94 24.86 9.57
05 6.35 46.83 31.99 4.35
06 5.74 58.56 13.20 5.77
07 4.98 109.00 13.51 2.96
08 3.45 61.28 7.79 3.93
09 6.71 55.03 15.41 6.51
10 6.62 62.00 18.66 5.78
11 3.81 86.58 22.36 2.80
12 3.10 96.61 10.38 1.98
13 5.37 62.35 12.67 4.88
14 3.52 42.56 16.08 4.77
15 4.76 56.74 13.86 4.85
16 5.11 63.85 14.36 4.19
17 3.88 69.94 19.47 3.40
Note. BV = blood volume, Q = blood flow, TA = time to arrival, rTA = 
relative time to arrival, MTT = mean transit time
Table 2. Correlation between Multiple Parameters of
Angiogenesis Analysis and MVD of Tumors
BV Q TA /rTA MTT
Correlation 0.529* 0.070 0.217 0.286
Spearman’s coefficient
rho (R)
MVD
P values
(2-tailed) 0.029 0.790 0.402 0.265
Note. * p < 0.05
MVD = microvessel density, BV = blood volume, Q = blood flow, TA = time
to arrival, rTA = relative time to arrival, MTT = mean transit timepower Doppler US differs substantially from the histologi-
cal MVDs (18). Contrast-enhanced US has been widely
studied for the evaluation of hepatic tumors, for the
diagnosis of testicular torsion or in the evaluation of
myocardial angiogenesis in patients following a myocardial
infarction (19 21). First-generation US contrast agents
were small, stabilized air microbubbles with a mean
diameter of 2 3 mm and contrast enhancement using first-
generation US contrast agents under a high MI relied more
on microbubble destruction than on the concentration of
the contrast agent (19). Second-generation US contrast
agents consist of 1 to 10  m (mean 2.5  m) microbubbles
that contain a hydrophobic gas in place of air (22). These
agents can circulate within the blood pool for a long time
without being destroyed, as they are much less soluble and
much more stable in the blood pool (23). Contrast-
enhanced US using a second-generation contrast agent
with a low MI can display the simple backscattering sound
wave of microbubbles with minimized bubble destruction
and permit prolonged evaluation of the hemodynamic
distribution of the contrast agent in real time without
serious complications (24 26).
Microvessel density is commonly used as a surrogate for
angiogenesis (1). Assessment of tumor angiogenesis is
important in predicting the prognosis of breast cancer
before treatment, and monitoring the response to
treatment (1 3). Assessment of tumor angiogenesis is also
important in selecting an optimal treatment for individual
patients and deciding an optimal drug dosage of an antian-
giogenic agent (27, 28). Imaging tumor angiogenesis is
more advantageous than measuring MVD directly as it is
noninvasive and can be used to assess much larger
volumes than biopsy samples (16, 29).
There are a few studies that have evaluated the quantifi-
cation of tumor angiogenesis, and most of the studies used
TICs derived from dynamic contrast-enhanced MRI (4 6,
16). Changes of hemodynamics in breast cancer after
treatment (16), and tumor perfusion in benign and
malignant breast tumors (31), as well as prognostic factors
of breast cancer have been evaluated with the use of
dynamic contrast-enhanced MRI (6, 32 34). A high
degree of contrast enhancement, rapid peak enhancement,
and peripheral enhancement pattern on MRI were
correlated with a higher tumor grade, advanced nodal
stage, and with active cellular proliferation (32 34).
However, MRI with dynamic contrast enhancement
represents the permeability of the vessels more than the
angiogenesis of the tumor (12, 30, 31). Moreover, some
studies showed no significant correlation between contrast
enhancement on MRI and tumor angiogenesis (10, 11), and
suggested that contrast enhancement on MRI could not be
explained solely by MVD, but from other contributing
factors (6, 10, 11).
In this study, we evaluated the quantification of tumor
angiogenesis using contrast-enhanced US, which is an
intravascular agent without diffusion (23). One hemody-
namic parameter, BV, from the TICs of contrast-enhanced
US showed a moderate degree of correlation (correlation
coefficient, 0.529) to MVD. In previous studies on the
hemodynamics of breast tumor using dynamic contrast-
enhanced MRI, similar results as compared to the present
study were seen, where the BV or ratio of BV between the
tumor and surrounding normal parenchyma were the most
meaningful parameters among all of the hemodynamic
parameters (4, 5). Although the degree of correlation
between BV and MVD was not high, this result suggests
that MVD can be imaged non-invasively and that the
quantification of tumor angiogenesis using contrast-
enhanced US is possible to achieve.
The degree of US contrast enhancement correlated with
MVD but did not correlate with the histological diagnosis
of the breast tumors. Previous studies using dynamic
contrast-enhanced MRI (31, 35), showed more rapid and
stronger contrast enhancement in malignant breast tumors.
However, the MVD did not differ between benign and
malignant breast tumors, as in previous studies (6, 31) and
the present study. The exact reason is still unknown, but
Kuhl et al. (31) suggested that the BV effect may be attrib-
utable to increased blood flow or an increased ratio of
Tumor Angiogenesis and Second-Generation US Contrast Medium in Rat Tumor Model
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Table 3. Pathological Diagnosis and MVD of Tumors
Number of 
Diagnosis
MVD 
Tumor (microvessels in 6 HPF)
01 IDC 176
02 IDC 122
03 IDC 137
04 IP 105
05 IP 119
06 IDC 064
07 IDC 105
08 IDC 064
09 IDC 058
10 IDC 092
11 IP 028
12 IP 036
13 IP 027
14 IP 044
15 IDC 050
16 IDC 100
17 IDC 028
Note. IP = intraductal proliferation, IDC = invasive ductal carcinoma
MVD = microvessel density, HPF = high power fieldsperfused versus non-perfused capillaries.
Based on our findings, we suggest that imaging of MVD
using contrast-enhanced US should not be used as a
method of differential diagnosis between benign and
malignant breast tumors, but should be considered as
representative of tumor angiogenesis in both benign and
malignant breast tumors, and is useful for the detection of
vascular changes in tumors.
This study has some limitations. The SonoVue contrast
agent produces the best images with the combination of a
low MI around 0.1 and a low MHz transducer around 4
MHz (36); but we used a 10-MHz transducer with a low
MI of 0.12 due to the lesion characteristics of the rat breast
tumors that were small lesion with superficial locations in
our study. 
Another limitation was the method of MVD assessment.
The histological diagnosis of the tumor was based on the
areas representative of invasive tumor components in
malignant lesions. However, when we counted the number
of mircovessels within the tumor in six high power fields,
including both the periphery and center of the tumor, the
more invasive foci as well as the less invasive areas were
included among the counted high power fields. Therefore,
tumors with a small malignant portion within a large area
of benign lesion were histologically diagnosed as IDCs, but
the MVD of the tumors represented the entire tumor, not
just the small malignant portion of the tumor. This may
influence the result of correlation between the MVD and
pathological diagnosis of the tumor. Finally, the degree of
contrast enhancement in contrast-enhanced US is largely
influenced by technical conditions, including acoustic
shadow, acoustic pressure, depth of the lesion, and
echogenicity of the surrounding tissue (37, 38). Poor
images caused by technical difficulties result in the poor
detection of the contrast signal that represents angiogene-
sis. All of these factors influence the quantitative analysis
of contrast-enhanced US. Therefore, to use contrast-
enhanced US for the quantification of tumor angiogenesis,
more studies are needed to establish proper technical
imaging conditions and analysis methods.
In conclusion, BV, one hemodynamic parameter derived
from the TICs of contrast-enhanced US, correlates with
MVD of the rat breast tumors. This finding suggests that
the quantification of tumor angiogenesis is possible with
the use of contrast-enhanced US using second-generation
contrast agents.
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